4.1.4 - Biological explanations and drug therapy for OCD

Biological vulnerability

The AQA requirement is focused: explain OCD using genetic explanations and neural explanations, then explain drug therapy as a biological treatment. You do not need a full clinical diagnosis lesson here, but you do need to link biology to the symptoms already taught: obsessions, compulsions, anxiety and disruption to everyday functioning.

AO1: the core claim

The biological approach argues that some people are more vulnerable to OCD because of inherited genetic differences and differences in brain systems involved in threat detection, habit, inhibition and mood regulation. Drug therapy follows the same logic: if OCD is partly linked to neurochemical functioning, then altering neurotransmitter activity may reduce symptoms.

AO2: applied example

Amira repeatedly checks that the hob is off before leaving for college. A biological explanation would not say that she "chooses" to do this. It would look for vulnerability factors such as a family history of OCD, altered serotonin functioning, and overactivity in brain circuits that keep signalling that something may be unsafe.

AO3: exam warning

Biological explanations are useful, but AQA answers should avoid biological determinism. Genes and neural circuits increase vulnerability; they do not guarantee that a person will develop OCD. Psychological learning, stress, family responses and cognitive interpretations may also matter.

Genetic explanations

Genetic evidence asks whether greater genetic similarity is associated with greater similarity in OCD, rather than assuming that family resemblance proves inheritance.

AO1: genes as vulnerability, not destiny

The most exam-safe wording is that OCD has a genetic component. Family and twin studies show that OCD tends to run in families, and that identical twins are more similar for OCD symptoms than non-identical twins. This suggests that genetic similarity contributes to risk.

However, OCD is not caused by a single "OCD gene". It is better described as polygenic: many genetic variations may each add a small amount of risk. Candidate genes have been investigated in serotonin, dopamine and glutamate systems, including genes linked to serotonin transport and receptors, COMT, and the glutamate transporter gene SLC1A1. These were historically plausible candidates, not an established list of causal ‘OCD genes’. Modern genome-wide studies test variants across the genome rather than selecting only a few candidates; their findings support a complex polygenic picture.

Research support

Browne, Gair, Scharf and Grice (2014) reviewed genetic evidence for OCD and related disorders. They reported that twin and family studies support a significant genetic contribution. Heritability estimates across studies vary, and first-degree relatives of people with OCD show higher rates of OCD than the general population. Heritability concerns variation in a studied population under its environmental conditions; it is not the percentage of one person’s OCD caused by genes.

AO3: limitations

Family resemblance is not pure genetic evidence. Relatives often share environments, such as parental modelling, stress patterns and family accommodation of rituals. Twin studies improve the evidence, but even identical twins may be treated more similarly than non-identical twins. Also, the incomplete and mixed candidate-gene evidence means the genetic explanation is stronger as a general vulnerability account than as a precise map of exactly which genes cause OCD.

Interpreting greater twin similarity

Identical twins share approximately all their inherited DNA, while non-identical twins share on average about half of their segregating variants. If identical twins are more similar for OCD under comparable environmental conditions, that pattern supports a genetic contribution. Similarity below 100% is compatible with environmental influences, development and measurement differences; it does not make genes irrelevant.

A 2025 genome-wide association meta-analysis compared 53,660 cases with more than two million controls and identified 30 associated genomic regions. This strengthens evidence of many genetic contributions, but an associated region may contain several genes and is not proof that one variant causes a person's symptoms. The study illustrates the evidence, not a list of loci to memorise.

Neural explanations

Neural accounts consider chemical signalling and interacting brain circuits. These are explanatory models, not brain-scan tests that establish OCD in an individual.

AO1: serotonin and neurochemistry

The classic AQA-level neural explanation focuses on serotonin. Serotonin is a neurotransmitter involved in mood regulation and flexible control of behaviour. A simplified account says that low or abnormal serotonin functioning may make it harder for a person to regulate anxiety and intrusive thoughts.

A more careful interpretation is that serotonin-targeting medication can reduce symptoms, but treatment response does not establish that low serotonin originally caused OCD. The exact causal mechanism is not fully settled. Dopamine and glutamate may also be involved, so a high-quality answer should avoid treating serotonin as the whole story.

AO1: the CSTC circuit

Many modern neural accounts focus on the cortico-striato-thalamo-cortical circuit, often shortened to CSTC. A revision-friendly version is:

• The orbitofrontal cortex (OFC) is involved in evaluating possible threat or error, such as "the door may not be locked".
• The caudate nucleus, part of the striatum, helps regulate or filter signals from the OFC.
• The thalamus relays signals back to cortical areas.
• If this loop becomes overactive or poorly filtered, threat/error signals may keep returning, making intrusive worries feel urgent and hard to dismiss.

In the checking example, the person may check the lock, feel temporary relief, but the "not safe yet" signal returns. The compulsion is then repeated.

AO3: cause and effect problem

Brain scans can show differences in people with OCD, including altered activity in CSTC regions such as the OFC, striatum and caudate. This supports the neural explanation, but it does not prove direction of causality. Repeated compulsions and anxiety could change brain activity, brain differences could increase symptoms, or both could be affected by a third factor such as genetic vulnerability or stress.

The ‘worry loop’ is a simplified functional model. Real CSTC pathways include excitatory and inhibitory connections and several interacting loops; the caudate is not literally a single broken gate. Brain-region functions are also broader than one symptom. A careful application says that altered circuit functioning could contribute to repetitive threat processing; it cannot infer a person's scan results from checking behaviour alone.

Drug therapy

Drug therapy aims to change neurochemical functioning so that symptoms become less severe.

AO1: SSRIs

The main biological treatment for OCD is the use of selective serotonin reuptake inhibitors, or SSRIs. Examples include fluoxetine and sertraline. The mechanism, rather than memorising a list of medicines, is the central learning here.

At a synapse, serotonin is released from the presynaptic neuron and binds to receptors on the postsynaptic neuron. Normally, some serotonin is reabsorbed by the presynaptic neuron. SSRIs inhibit transporter-mediated reuptake; they do not make the neuron release extra serotonin directly. This leaves more serotonin available in the synaptic gap. Over time, changed signalling may reduce anxiety and intrusive obsessive thoughts, making compulsions easier to resist.

AO1: other biological drug options

If SSRIs do not help enough, clinical guidance may consider alternatives such as another SSRI or clomipramine, a tricyclic drug with strong serotonin reuptake effects. Antipsychotic augmentation may be used in specialist treatment for some treatment-resistant cases, but for this AQA bullet the core treatment is drug therapy through serotonin reuptake inhibition.

AO2: treatment in context

If an adult has moderate OCD and chooses medication, an SSRI might be prescribed and monitored. The treatment would not remove all stress instantly: NICE guidance for adults notes that benefit can take up to about 12 weeks. If symptoms are severe, guidance may recommend combined treatment, such as an SSRI plus CBT with exposure and response prevention.

AO3: effectiveness and appropriateness

Soomro et al. (2008) reviewed 17 randomised studies with 3097 adult participants and found SSRIs more effective than placebo in reducing OCD symptoms in the short term. This is strong practical support because it uses randomised controlled trials rather than only case reports.

There are still limitations. Some people do not respond, benefits may take weeks, and side effects such as nausea, insomnia, headaches or agitation can reduce adherence. Medication may also reduce symptoms without directly teaching the person new ways to respond to obsessive thoughts, so combined psychological and biological treatment can be more appropriate for some people.

From a trial result to a justified conclusion

Random allocation helps make treatment groups comparable before medication. A placebo comparison helps separate the drug effect from expectations, contact with clinicians and change over time. If the SSRI group improves more, this supports a treatment effect under the trial conditions. It does not show that every participant responds or that the original cause was a serotonin deficiency: changing a signalling system can help symptoms even when the initial problem arose through several routes.

The short-term SSRI review cannot by itself answer every long-term question about relapse, adherence or sustained benefit. Distinguish symptom improvement during treatment from cure, and a delayed clinical effect from the more immediate transporter-blocking action.

Evaluating biological explanations and treatment

Different research methods provide different kinds of evidence. Agreement between them can strengthen an account, but each method still has its own limits.

AO3: strength - research support from several methods

The biological approach is supported by converging evidence. Twin and family studies suggest genetic vulnerability. Brain-imaging and review evidence links OCD to CSTC circuits and serotonin systems. Drug trials show SSRIs can reduce symptoms better than placebo. This triangulation makes the biological approach more credible than a single-study explanation.

AO3: limitation - reductionism

The biological approach can be reductionist if it explains OCD only through genes and neurotransmitters. OCD also involves meanings, fears, avoidance and reinforcement. For example, handwashing may be maintained because it reduces anxiety in the short term, and intrusive thoughts may be made worse by catastrophic interpretations. A stronger account is interactionist: biological vulnerability may make symptoms more likely, while psychological processes shape the content and maintenance of symptoms.

AO3: limitation - determinism and ethics

A purely biological account risks making OCD sound inevitable. This may reduce blame, which is helpful, but it may also encourage pessimism if students write as if people are controlled by their genes or brain circuits. In reality, treatment can help, and people can learn strategies to manage symptoms. Good exam answers describe biological vulnerability without removing agency or ignoring treatment choice.

AO3: treatment evaluation

Drug therapy is often accessible, can be combined with CBT, and is useful when symptoms are severe enough to prevent engagement with therapy. It also has economic advantages because medication may require fewer therapist hours than intensive psychological treatment. However, drug therapy can have side effects, may not work for everyone, and may be less acceptable to people who prefer psychological approaches. NICE guidance reflects this by recommending treatment choices based on impairment, preference and response.

Quick recap

Genes can increase vulnerability without fixing an outcome. Neural models describe altered signalling and circuits, while SSRIs inhibit presynaptic serotonin reuptake and can reduce symptoms over time. Twin resemblance, brain associations and randomised treatment effects answer different questions; none alone proves a single cause of OCD.